Vivitrol isn't dead because of incompetent leadership. It isn't dead at all...but it is on life-support. Like every other medication ever created, it has run its life-cycle, and revenue growth has plateaued. "Leadership" can't improve its effectiveness nor can "Leadership" create another indication. And those are the two biggest limiting factors to revenue growth. Sales has done an excellent job in spreading the gospel...virtually every prescriber in the addiction space knows about it...so there isn't any low-hanging...or even medium-hanging, fruit left to pick.
Where leadership dropped the ball was in assuming the growth we got in the initial years after the OUD indication was going to last forever...and then growing headcount based on that assumption. They dropped the ball by not creating a detox protocol + kit to help pts get through detox. They dropped the ball by not partnering with the Bridge for detox. They dropped the ball by not developing a legal, effective, DTC campaign. Now, that doesn't mean that didn't try each of the tactics...they may have. But they didn't produce any of them.
I've heard criticism that they should have done more studies...assuming those studies would have produced more compelling results. But my guess is they did do additional studies...and the results weren't sufficient enough to warrant publication.